Imatinib

About

Therapy type: Targeted therapy

Therapy strategy: Bcr-Abl inhibition, c-Kit inhibition, PDGF-R inhibition

Mappings

NCI Thesaurus: Imatinib (coding:ncit:C62035)

RxNorm: imatinib (coding:rxcui:282388, coding:omop:4185917)

SNOMED: Imatinib (coding:sctid:414460008, coding:omop:1304107)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations Biomarkers Cancer types Therapies
FDA (2) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
EMA (2) FDA (2) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Imatinib
FDA (2) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
EMA (1) FDA (1) PDGFRA rearrangements Myelodysplastic Syndromes Imatinib
EMA (1) FDA (1) PDGFRB rearrangements Myelodysplastic Syndromes Imatinib
FDA (1) not KIT p.D816V Aggressive Systemic Mastocytosis Imatinib
EMA (1) FDA (1) FIP1L1::PDGFRA Chronic Eosinophilic Leukemia, NOS Imatinib
EMA (2) FDA (1) CD117 + Gastrointestinal Stromal Tumor Imatinib
FDA (1) FIP1L1::PDGFRA Gastrointestinal Stromal Tumor Imatinib
EMA (2) not BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
EMA (2) not BCR::ABL1 Acute Lymphoid Leukemia Imatinib
EMA (1) PDGFRA rearrangements Myeloproliferative Neoplasm Imatinib
EMA (1) PDGFRB rearrangements Myeloproliferative Neoplasm Imatinib
HSE (1) BCR::ABL1 Acute Lymphoid Leukemia Daunorubicin, Dexamethasone, Imatinib, Methotrexate, Vincristine
HSE (1) BCR::ABL1, CD20 + Acute Lymphoid Leukemia Daunorubicin, Dexamethasone, Imatinib, Methotrexate, Rituximab, Vincristine